Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) to treat locally advanced or metastatic R 16 November 2023
Merck & Co has secured another approval from the US Food and Drug Administration for its blockbuster immuno-oncology product, Keytruda (pembrolizumab). 1 November 2023
Swiss pharma major Novartis (NOVN: VX) has secured another approval from the US regulator for Cosentyx (secukinumab), a biologic which blocks the IL-17A cytokin 1 November 2023
In briefing notes released ahead of a key meeting on Tuesday, scientists at the US Food and Drug Administration describe uncertainty in the risks associated wit 30 October 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.